Mendel AI Joins NVIDIA Inception Program to Accelerate AI Innovations in Life Sciences
July 15 2024 - 11:00AM
Business Wire
Mendel AI, a leader in clinical AI for the life sciences
industry, today announced it has joined NVIDIA Inception, a program
that nurtures startups revolutionizing industries with
technological advancements.
By joining NVIDIA Inception, Mendel will receive access to
NVIDIA’s industry-leading technology, including the latest NVIDIA
NIM inference microservices to accelerate Mendel's Hypercube AI
solution, and technical expertise in artificial intelligence, deep
learning and data science. The resources from the program will help
Mendel bring sophisticated, reliable and explainable AI solutions
to the healthcare sector that are not only powerful but also
responsible and tailored to meet the high stakes of medical
decision-making.
"We are incredibly excited to share that Mendel AI has joined
NVIDIA Inception, marking a significant milestone in our ongoing
efforts to redefine the possibilities of AI in healthcare," said
Karim Galil, CEO of Mendel AI. "By integrating NVIDIA's
cutting-edge AI tools, we aim to enhance our platform's
capabilities, specifically in processing and understanding complex,
unstructured medical data at an unprecedented scale. With the
program’s resources and together with other forward-thinking
companies, we are committed to pushing the boundaries of what AI
can achieve in medical research and patient care, aiming to ensure
that our technology continues to lead the way in efficiency and
effectiveness."
Mendel’s innovative approach to creating clinician-like AI was
included in a recent NVIDIA blog post, highlighting Mendel’s
applications across clinical research, real-world evidence
generation and cohort selection.
NVIDIA Inception helps startups during critical stages of
product development, prototyping and deployment. Every Inception
member gets a custom set of ongoing benefits, such as NVIDIA
Training credits, preferred pricing on NVIDIA hardware and
software, and technological assistance, which provides startups
with the fundamental tools to help them grow.
About Mendel AI:
Mendel AI supercharges clinical data workflows by coupling large
language models with a proprietary clinical hypergraph, delivering
scalable clinical reasoning without hallucinations and ensuring
100% explainability. Headquartered in San Jose, California, Mendel
is backed by blue-chip investors, including Oak HC/FT and DCM.
For more information, visit www.mendel.ai or contact
marketing@mendel.ai.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240715061760/en/
Media Contact Sylvia Aranda (on behalf of Mendel)
saranda@realchemistry.com